Navigation Links
Angiotech wins before the UK House of Lords
Date:7/10/2008

such forward-looking statements. Page 1 of 2 Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions, both nationally and in the regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; adverse results or unexpected delays in drug discovery and clinical development processes; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development and to expand commercialization activities or consummate acquisitions; and any other factors that may affect performance. In addition, our business is subject to certain operating risks that may cause the actual results expressed or implied by the forward-looking statements in this report to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete preclinical and clinical development of our products; changes in business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the deve
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... State University have developed a technique for controlling the ... voltages, opening the door to a new generation of ... hinges on the fact that the oxide "skin" of ... acts as a surfactant, lowering the surface tension ... researchers used a liquid metal alloy of gallium and ...
(Date:9/15/2014)... MORRISVILLE, NC (PRWEB) September 15, 2014 ... newly developed deep imaging OCT system for the optical ... , The EnvisuTM S4410 SDOCT for Contact ... measurements for standard and high complexity contact lens, IOL ... allows imaging of a complete contact lens immersed in ...
(Date:9/15/2014)... The chemistry, taste, and health effects of tea can vary ... the nonprofit American Botanical Council (ABC). Recent research by ... on the phytochemical compounds in tea ( Camellia sinensis ) ... in the Yunnan province of southwestern ... future of medicinal botanicals. Dr. Ahmed,s report on ...
(Date:9/15/2014)... septiembre de 2014 La segunda anual International ... 12 al 18 de octubre. Como iniciativa conjunta de la ... compañías miembro s, la IPAW se ha diseñado para: ... a la colección de fuentes de plasma , Reconocimiento ... y mejorar las vidas , Aumento del conocimiento sobre ...
Breaking Biology Technology:Researchers control surface tension to manipulate liquid metals 2Bioptigen Introduces Deep Imaging OCT System for Contact Lens Metrology 2Tea Taste and Quality Affected by Climate Change 2Tea Taste and Quality Affected by Climate Change 3Tea Taste and Quality Affected by Climate Change 4La International Plasma Awareness Week será una celebración para los donantes 2La International Plasma Awareness Week será una celebración para los donantes 3
... Ondine Biopharma,Corporation (the "Company" or "Ondine", TSX: ... photodisinfection based products, today,announced its financial results ... 2008., "During the past quarter we ... photodisinfection technology and we are leveraging our,successes ...
... 14 Palatin Technologies,Inc. (Amex: PTN ) ... clinical,trial of PL-3994, a novel, long-acting natriuretic peptide ... heart failure (HF). The,Phase 2a trial was a ... volunteers with controlled hypertension who,received the medication or ...
... professor of aerospace and ocean engineering at Virginia Tech, ... E. Powe Junior Faculty Award. The award will support ... are new material and structural systems that have the ... "I believe these innovative materials will lead to new ...
Cached Biology Technology:Ondine Biopharma Announces Second Quarter 2008 Financial Results 2Ondine Biopharma Announces Second Quarter 2008 Financial Results 3Ondine Biopharma Announces Second Quarter 2008 Financial Results 4Ondine Biopharma Announces Second Quarter 2008 Financial Results 5Ondine Biopharma Announces Second Quarter 2008 Financial Results 6Ondine Biopharma Announces Second Quarter 2008 Financial Results 7Ondine Biopharma Announces Second Quarter 2008 Financial Results 8Ondine Biopharma Announces Second Quarter 2008 Financial Results 9Ondine Biopharma Announces Second Quarter 2008 Financial Results 10Ondine Biopharma Announces Second Quarter 2008 Financial Results 11Ondine Biopharma Announces Second Quarter 2008 Financial Results 12Ondine Biopharma Announces Second Quarter 2008 Financial Results 13Ondine Biopharma Announces Second Quarter 2008 Financial Results 14Ondine Biopharma Announces Second Quarter 2008 Financial Results 15Ondine Biopharma Announces Second Quarter 2008 Financial Results 16Ondine Biopharma Announces Second Quarter 2008 Financial Results 17Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure 2Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure 3
(Date:9/15/2014)... PULLMAN, Wash.Washington State University researchers have found "the most ... that can be used to transfer valuable genes ... the way for breeders to develop wheat varieties with ... a legion of genetic tools that can reduce crop ... hurdles and controversy of Genetically Modified Organisms, or GMOs., ...
(Date:9/15/2014)... understand how the fish communities might shift under ... of environmental data to inform future decisions relating ... said Paula Whitfield, a research ecologist at NOAA,s ... lead author of the study. , The North ... where historically, both temperate and tropical species live, ...
(Date:9/15/2014)... the Department of Science and Technology in Society in ... Virginia Tech, has won a 2014 National Science Foundation ... and problems of creating a global nuclear emergency response ... Nuclear Power Plant in March 2011 was a turning ... Schmid said. Three of the plant,s six nuclear reactors ...
Breaking Biology News(10 mins):WSU researchers find 'most famous wheat gene' 2Study finds warming Atlantic temperatures could increase range of invasive species 2'Nuclear disasters don't respect national boundaries' 2
... German . Scientists at the Max Planck ... insights for stem cell research which are also applicable to ... treatments. As Rolf Kemler,s research group discovered, a molecular link ... telomeres and a signalling pathway known as the Wnt/β-signalling pathway. ...
... smaller than the nano as it is the equivalent of ... green algae of this imperceptible size existing in the Bilbao ... estuary. This has enabled him to identify six genera and ... been catalogued in these waters. He has also put forward ...
... toward treating disease with minute capsules containing not drugs ... making the drug. In an article in ACS, journal ... nano-sized capsules that contain the genetically coded instructions, plus ... that can be switched on with an external signal. ...
Cached Biology News:A nanoscopic look at the estuary's green algae 2A nanoscopic look at the estuary's green algae 3
Immunogen: Secretory component isolated from human colostrum. Storage: 4 C...
... PinPoint™ Vector Sequencing Primer is designed for ... Vectors (Cat.# V2031, V2051, V2061). The primer ... at nucleotides 325343, approximately 4050 base pairs ... can be used to determine if an ...
Negative Control, eluted and packaged aseptically in 20l of 10mM Tris-HCL, pH 8.0, 1 mM EDTA, 5 years at either 4°C or -20°C...
Medium for cryopreserving subcutaneous or omental preadipocytes...
Biology Products: